The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Previous

NS5a Replication Complex Inhibitor Will Be Used in Future Studies

Back to News Homepage

Next

When Hepatitis C Drugs Impact Your Thyroid

A New Combination of Hepatitis C Drugs Leading to High Remission Rates

October 16, 2013

Print this page

In phase 2 trials, the addition of the drug danoprevir to the current treatment regimen for patients with Hepatitis C showed an 85 percent sustained virologic response rate.

New hepatitis C drug shows potential in phase 2 trials

Posted By News On October 10, 2013

Bethesda, MD — The addition of danoprevir to the current treatment regimen for patients with hepatitis C leads to high rates of remission, according to a new article in Gastroenterology, the official journal of the American Gastroenterological Association. The current standard of care for hepatitis C patients includes a combination of peginterferon and ribavirin.

“Despite recent advances, the current hepatitis C treatment regimen is burdensome on the patient and prone to adverse events,” said Patrick Marcellin, lead study author from the Service d’Hépatologie and Inserm CRB3, Hôpital Beaujon, APHP University of Paris. “The promising results from this study offer hope that danoprevir can improve the quality of life for patients suffering from this disease.”

Continue reading this entire article:
http://www.sciencecodex.com/new_hepatitis_c_drug_shows_potential_in_phase_2_trials-120853

3 Comments
Share
Share

Previous

NS5a Replication Complex Inhibitor Will Be Used in Future Studies

Back to News Homepage

Next

When Hepatitis C Drugs Impact Your Thyroid

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.